ONCOLife’s New Edition Is Live with Exclusive Interviews and Breakthroughs in Cancer Research

The new issue of ONCOLife is now available — featuring innovative advances, exclusive expert interviews, and the latest regulatory updates that are shaping the future of cancer treatment. With a focus on cancer vaccines, targeted therapies, and next-generation technologies, this issue offers a panoramic view of oncology’s most exciting frontiers.

Click here to read the latest issue

Accelerating Cancer Vaccine Research

A standout feature is our exclusive interview with Susanna Greer of the V Foundation for Cancer Research and Kristen Dahlgren, founder of the Cancer Vaccine Coalition. Together, they share insights on their groundbreaking collaboration to advance breast cancer vaccine research. Their partnership is not only accelerating clinical trials but also redefining the landscape of survivorship and precision medicine.

Water Vapor Ablation: A Minimally Invasive Approach

In another exclusive, Michael Kujak, CEO of Francis Medical, details the VAPOR 2 trial investigating water vapor ablation for prostate cancer. With FDA Breakthrough Device Designation and encouraging early data, this novel approach could redefine standards of care across prostate, kidney, and bladder cancers.

Expanding Clinical Trial Access with START & CURC

We also spotlight how the integration of the Carolina Urologic Research Center (CURC) into the START global network is transforming GU oncology research. In an in-depth discussion, Nick Slack, CEO of START, outlines how embedding trials in urology practices and leveraging PDX models are accelerating translational research on a global scale.

Next-Generation Therapies and ADCs

Dr. Eleni Lagkadinou, Vice President at AbbVie, discusses the company’s latest strides in oncology R&D, from innovative antibody-drug conjugates to novel immuno-oncology platforms. Early insights into investigational therapies ABBV-969 and ABBV-514 underscore AbbVie’s mission to tackle hard-to-treat cancers.

Some of the Hot Topics in This Issue

This edition also covers some of the most important global oncology updates:

• CAR-T therapy linked to secondary cancers – global data raises monitoring concerns
• Genetic testing advances safety and reduces chemotherapy toxicity in GI cancers
• New Study Uncovers Hidden Disease in 42% of Ovarian Cancer Patients in Remission
• Ferroptosis as a New Strategy: Iron-Driven Cell Death Targets Cancer Stem Cells
• FDA approvals: Zongertinib in HER2+ NSCLC, Izalontamab Brengitecan for EGFR-mutant lung cancer
• Breakthroughs in mRNA vaccines, ferroptosis research, and bispecific antibodies in hematology
• mRNA Vaccines Plus Checkpoint Inhibitors Shows Curative Potential in Gastric Cancer
• New Radioimmunotherapy Strategy Eradicates Cancer Stem Cells in Ovarian Cancer